Skip to main content
. Author manuscript; available in PMC: 2021 May 19.
Published in final edited form as: Cancer Lett. 2019 Jan 11;445:34–44. doi: 10.1016/j.canlet.2019.01.001

Fig. 2. Midostaurin re-sensitizes ABCB1-overexpressing cells to substrate chemotherapy drug of ABCB1.

Fig. 2.

Parental HEK293 cells (A - C, left panels), MDR19-HEK293 cells (A, right panel), MRP1-HEK293 cells (B, right panel) and R482-HEK293 cells (C, right panel) were treated with increasing concentrations of ABCB1 substrate chemotherapy drug paclitaxel, ABCC1 substrate chemotherapy drug etoposide, or ABCG2 substrate chemotherapy drug SN-38, respectively, in the presence of DMSO (open circles), or midostaurin at 20 nM (open squares) or at 50 nM (filled squares), or a reference inhibitor as a positive control (filled circles). (D) Drug-sensitive parental KB-3–1 cancer cells (left panel) and ABCB1-overexpressing variant KB-V1 cancer cells (right panel), (E) drug-sensitive parental OVCAR-8 cancer cells (left panel) and ABCB1-over-expressing variant NCI-ADR-RES cancer cells (right panel) were treated with paclitaxel in the presence of DMSO (open circles), or midostaurin at 50 nM (open squares) or at 100 nM (filled squares) or at 200 nM (open triangles). Points, mean values from at least three independent experiments; bars; S.E.M.